Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 11, 2017. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| May 10, 2017 | Ordinary Shares (25p each) | £16.1473 | 140 shares (aggregate) | London Stock Exchange |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine equity compensation transactions for ten senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of ordinary shares under the ShareReward Plan, consisting of partnership shares and matching shares.
- Participants: Transactions involved 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Volume: Most executives acquired 16 shares (8 partnership + 8 matching), while two executives (Mr N Hirons and Dr P J T Vallance) acquired 14 shares (7 partnership + 7 matching).
- Pricing: All shares were acquired at a uniform price of £16.1473.
- Scope: This filing does not contain financial performance data; investors should refer to the company's Form 20-F or quarterly reports for revenue and earnings information.